GRAS Screen™ 5 and 6 were developed by Hampton Research for the crystallization of proteins, including monoclonal antibodies.
Each of the chemicals in GRAS Screen 5 and 6 has been used under one or more of the following categories. As (1) a Generally Recognized As Safe (GRAS) substance, (2) a pharmaceutical excipient, (3) a normal physiological constituent, (4) a metabolic byproduct, and/or (5) a Everything Added to Food in the United States (EAFUS) substance.
GRAS Screen 5 samples four low molecular weight Polyethylene glycols (300, 400, MME 550, and 600) at three concentrations versus eight unique buffers encompassing pH 4.5 to 10. GRAS Screen 5 is supplied in a 96 Deep Well block format and is compatible with robotic and multi-channel pipet liquid handling systems. GRAS Screen 5 is compatible with vapor diffusion, free interface diffusion, and microbatch crystallization methods. For research use only.
GRAS Screen 6 samples four medium molecular weight Polyethylene glycols (1,000, MME 2,000, 3,350, & 4,000) at three concentrations versus eight unique buffers encompassing pH 4.5 to 10. GRAS Screen 6 is supplied in a 96 Deep Well block format and is compatible with robotic and multi-channel pipet liquid handling systems. GRAS Screen 6 is compatible with vapor diffusion, free interface diffusion, and microbatch crystallization methods. For research use only.
1 ml, Deep Well block format
1 ml, Deep Well block format
1. Optimization of crystallization conditions for biological macromolecules. Alexander McPherson and Bob Cudney. Acta Crystallographica Section F Volume 70, Issue 11, pages 1445-1467, November 2014.
2. Crystallization of intact monoclonal antibodies. Harris LJ, Skaletsky E, McPherson A. Proteins. 1995 Oct;23(2):285-9.
3. Crystalline monoclonal antibodies for subcutaneous delivery. Yang MX1, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6934-9.
4. Fast and Scalable Purification of a Therapeutic Full-Length Antibody Based on Process Crystallization. Dariusch Hekmat et al, Biotechnology and Bioengineering, Vol. 110, No. 9, September, 2013.
5. Towards Protein Crystallization as a Process Step in Downstream Processing of Therapeutic Antibodies: Screening and Optimization at Microbatch Scale. Yuguo Zang et al, PLoS One. 2011; 6(9): e25282.
6. Crystallization as a tool for bioseparation. Bob Cudney, Am Biotechnol Lab. 1994 Jun;12(7):42.
7. Large-scale crystallization of proteins for purification and formulation. Hekmat D. Bioprocess Biosyst Eng. 2015 Jul;38(7):1209-31. doi: 10.1007/s00449-015-1374-y
8. Using X-Ray Crystallography to Simplify and Accelerate Biologics Drug Development. Brader ML, Baker EN, Dunn MF, Laue TM, Carpenter JF. J Pharm Sci. 2017 Feb;106(2):477-494. doi: 10.1016/j.xphs.2016.10.017.
9. Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions. Sandeep Nema and Ronald J. Brendell, PDA J Pharm Sci and Tech 2011, 65 287-332.